These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 10432391

  • 1. Polarized expression of the vasopressin V2 receptor in Madin-Darby canine kidney cells.
    Andersen-Beckh B, Dehe M, Schülein R, Wiesner B, Rutz C, Liebenhoff U, Rosenthal W, Oksche A.
    Kidney Int; 1999 Aug; 56(2):517-27. PubMed ID: 10432391
    [Abstract] [Full Text] [Related]

  • 2. Vasopressin V2 receptor mutants that cause X-linked nephrogenic diabetes insipidus: analysis of expression, processing, and function.
    Oksche A, Schülein R, Rutz C, Liebenhoff U, Dickson J, Müller H, Birnbaumer M, Rosenthal W.
    Mol Pharmacol; 1996 Oct; 50(4):820-8. PubMed ID: 8863826
    [Abstract] [Full Text] [Related]

  • 3. Polarized cell surface expression of the green fluorescent protein-tagged vasopressin V2 receptor in Madin Darby canine kidney cells.
    Schülein R, Lorenz D, Oksche A, Wiesner B, Hermosilla R, Ebert J, Rosenthal W.
    FEBS Lett; 1998 Dec 18; 441(2):170-6. PubMed ID: 9883878
    [Abstract] [Full Text] [Related]

  • 4. Appropriate polarization following pharmacological rescue of V2 vasopressin receptors encoded by X-linked nephrogenic diabetes insipidus alleles involves a conformation of the receptor that also attains mature glycosylation.
    Tan CM, Nickols HH, Limbird LE.
    J Biol Chem; 2003 Sep 12; 278(37):35678-86. PubMed ID: 12824183
    [Abstract] [Full Text] [Related]

  • 5. Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model.
    Robben JH, Knoers NV, Deen PM.
    Am J Physiol Renal Physiol; 2005 Aug 12; 289(2):F265-72. PubMed ID: 16006591
    [Abstract] [Full Text] [Related]

  • 6. Reconstitution of mutant V2 vasopressin receptors by adenovirus-mediated gene transfer. Molecular basis and clinical implication.
    Schöneberg T, Sandig V, Wess J, Gudermann T, Schultz G.
    J Clin Invest; 1997 Sep 15; 100(6):1547-56. PubMed ID: 9294123
    [Abstract] [Full Text] [Related]

  • 7. The role of conserved extracellular cysteine residues in vasopressin V2 receptor function and properties of two naturally occurring mutant receptors with additional extracellular cysteine residues.
    Schülein R, Zühlke K, Oksche A, Hermosilla R, Furkert J, Rosenthal W.
    FEBS Lett; 2000 Jan 21; 466(1):101-6. PubMed ID: 10648821
    [Abstract] [Full Text] [Related]

  • 8. Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co-expressed receptor polypeptide.
    Schoneberg T, Yun J, Wenkert D, Wess J.
    EMBO J; 1996 Mar 15; 15(6):1283-91. PubMed ID: 8635461
    [Abstract] [Full Text] [Related]

  • 9. Molecular aspects of vasopressin receptor function.
    Schöneberg T, Kostenis E, Liu J, Gudermann T, Wess J.
    Adv Exp Med Biol; 1998 Mar 15; 449():347-58. PubMed ID: 10026824
    [Abstract] [Full Text] [Related]

  • 10. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
    Robben JH, Sze M, Knoers NV, Deen PM.
    Am J Physiol Renal Physiol; 2007 Jan 15; 292(1):F253-60. PubMed ID: 16926443
    [Abstract] [Full Text] [Related]

  • 11. Dominant and recessive distal renal tubular acidosis mutations of kidney anion exchanger 1 induce distinct trafficking defects in MDCK cells.
    Cordat E, Kittanakom S, Yenchitsomanus PT, Li J, Du K, Lukacs GL, Reithmeier RA.
    Traffic; 2006 Feb 15; 7(2):117-28. PubMed ID: 16420521
    [Abstract] [Full Text] [Related]

  • 12. Properties of the human arginine vasopressin V2 receptor after site-directed mutagenesis of its putative palmitoylation site.
    Schülein R, Liebenhoff U, Müller H, Birnbaumer M, Rosenthal W.
    Biochem J; 1996 Jan 15; 313 ( Pt 2)(Pt 2):611-6. PubMed ID: 8573100
    [Abstract] [Full Text] [Related]

  • 13. The property of a novel v2 receptor mutant in a patient with nephrogenic diabetes insipidus.
    Inaba S, Hatakeyama H, Taniguchi N, Miyamori I.
    J Clin Endocrinol Metab; 2001 Jan 15; 86(1):381-5. PubMed ID: 11232028
    [Abstract] [Full Text] [Related]

  • 14. Mutations in the vasopressin V2 receptor gene in families with nephrogenic diabetes insipidus and functional expression of the Q-2 mutant.
    Rosenthal W, Seibold A, Antaramian A, Gilbert S, Birnbaumer M, Bichet DG, Arthus MF, Lonergan M.
    Cell Mol Biol (Noisy-le-grand); 1994 May 15; 40(3):429-36. PubMed ID: 7920187
    [Abstract] [Full Text] [Related]

  • 15. Binding-, intracellular transport-, and biosynthesis-defective mutants of vasopressin type 2 receptor in patients with X-linked nephrogenic diabetes insipidus.
    Tsukaguchi H, Matsubara H, Taketani S, Mori Y, Seido T, Inada M.
    J Clin Invest; 1995 Oct 15; 96(4):2043-50. PubMed ID: 7560098
    [Abstract] [Full Text] [Related]

  • 16. Calmodulin interacts with the V2 vasopressin receptor: elimination of binding to the C terminus also eliminates arginine vasopressin-stimulated elevation of intracellular calcium.
    Nickols HH, Shah VN, Chazin WJ, Limbird LE.
    J Biol Chem; 2004 Nov 05; 279(45):46969-80. PubMed ID: 15319442
    [Abstract] [Full Text] [Related]

  • 17. Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation.
    Prosperi F, Suzumoto Y, Marzuillo P, Costanzo V, Jelen S, Iervolino A, Guarino S, La Manna A, Miraglia Del Giudice E, Perna AF, Zacchia M, Cordat E, Capasso G, Trepiccione F.
    Sci Rep; 2020 Oct 02; 10(1):16383. PubMed ID: 33009446
    [Abstract] [Full Text] [Related]

  • 18. A low affinity vasopressin V2-receptor in inherited nephrogenic diabetes insipidus.
    Luzius H, Jans DA, Grünbaum EG, Moritz A, Rascher W, Fahrenholz F.
    J Recept Res; 1992 Oct 02; 12(3):351-68. PubMed ID: 1387165
    [Abstract] [Full Text] [Related]

  • 19. Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist.
    Makita N, Sato T, Yajima-Shoji Y, Sato J, Manaka K, Eda-Hashimoto M, Ootaki M, Matsumoto N, Nangaku M, Iiri T.
    J Biol Chem; 2016 Oct 21; 291(43):22460-22471. PubMed ID: 27601473
    [Abstract] [Full Text] [Related]

  • 20. [Nephrogenic diabetes insipidus].
    Ishikawa S.
    Nihon Rinsho; 1996 Mar 21; 54(3):819-24. PubMed ID: 8904243
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.